JAK2 and myelofibrosis: On the basis of extensive clinical data on myelofibrosis, a disease type that frequently harbors the JAK2 V617F mutation [150,151,152,153], JAK2-activating mutations may predict sensitivity to JAK2 inhibitors such as ruxolitinib.